Chromosome Disorders D025063

Description

Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)   MeSH

Subtype Terms (20)

22q11 Deletion Syndrome
7 drugs (6 approved, 1 experimental)

Angelman Syndrome
13 drugs (5 approved, 8 experimental)

Beckwith-Wiedemann Syndrome
8 approved drugs

Branchio-Oto-Renal Syndrome
 

Cri-du-Chat Syndrome
 

De Lange Syndrome
1 approved drug

Down Syndrome
68 drugs (54 approved, 14 experimental)

Holoprosencephaly
 

Jacobsen Distal 11q Deletion Syndrome
 

Prader-Willi Syndrome
32 drugs (15 approved, 17 experimental)

Rubinstein-Taybi Syndrome
1 approved drug

Sex Chromosome Disorders
1 approved drug

Silver-Russell Syndrome
1 approved drug

Smith-Magenis Syndrome
3 drugs (2 approved, 1 experimental)


Phase 4 Indicated Drugs (1)

Other Experimental Indicated Drugs (1)


Organization Involved with Phase 3 Indications (1)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.